Akarx Inc Drug Patent Portfolio
Akarx Inc owns 1 orange book drug protected by 3 US patents Given below is the list of Akarx Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7638536 | 2-Acylaminothiazole derivative or salt thereof | 28 Jul, 2027 | Active |
| US8338429 | 2-acylaminothiazole derivative or salt thereof | 30 Jun, 2023 | Expired |
| US8765764 | 2-acylaminothiazole derivative or salt thereof | 15 Jan, 2023 | Expired |
Latest Legal Activities on Akarx Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Akarx Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Patent Term Extension Certificate
Critical
| 08 Jan, 2024 | US7638536 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 26 Dec, 2023 | US7638536 |
| Requirement for information sent under 37 CFR 1.750 | 08 Dec, 2023 | US7638536 |
| Notice of Final Determination -Eligible | 16 Nov, 2023 | US7638536 |
|
FDA Final Eligibility Letter
Critical
| 14 Nov, 2023 | US7638536 |
| transaction for FDA Determination of Regulatory Review Period | 06 Feb, 2023 | US7638536 |
| transaction for FDA Determination of Regulatory Review Period | 02 Feb, 2023 | US7638536 |
|
Information Disclosure Statement (IDS) Filed
Critical
| 02 Feb, 2023 | US7638536 |
|
Interim Patent Term Extension Granted
Critical
| 11 Jan, 2023 | US7638536 |
|
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED
Critical
| 09 Jan, 2023 | US7638536 |
|
Terminal Disclaimer Filed
Critical
| 09 Jan, 2023 | US7638536 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Dec, 2021 | US8765764 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Jun, 2021 | US7638536 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2021 | US7638536 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jun, 2020 | US8338429 |
Akarx Inc's Family Patents
Akarx Inc drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 16.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Akarx Inc Drug List
Given below is the complete list of Akarx Inc's drugs and the patents protecting them.
1. Doptelet
Doptelet is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7638536 | 2-Acylaminothiazole derivative or salt thereof |
28 Jul, 2027
(2 years from now)
| Active |
| US8338429 | 2-acylaminothiazole derivative or salt thereof |
30 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US8765764 | 2-acylaminothiazole derivative or salt thereof |
15 Jan, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Doptelet's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List